PLI schemes attract ₹2.4 lakh crore investments, create 14.15 lakh jobs; exports cross ₹15.2 lakh crore: Govt

The Production Linked Incentive (PLI) schemes have attracted investments of more than ₹2.4 lakh crore, generated over 14.15 lakh direct and indirect jobs, and enabled cumulative exports exceeding ₹15.2 lakh crore since their launch, the government informed Parliament. 

In a written reply in the Lok Sabha, Minister of State for Commerce and Industry Jitin Prasada said the PLI schemes, launched across 14 key sectors with a total financial outlay of ₹1.91 lakh crore, are aimed at strengthening domestic manufacturing, attracting investments, boosting exports, creating employment, and improving India's global competitiveness. 

The Department for Promotion of Industry and Internal Trade (DPIIT) is the nodal agency for coordinating and monitoring the schemes, while the respective ministries are responsible for implementation. 

As of March 31, 2026, the PLI schemes had attracted actual investments of over ₹2.4 lakh crore and created more than 14.15 lakh jobs, both direct and indirect, the minister said. 

The government said the schemes have collectively enabled exports of over ₹15.2 lakh crore since inception, with cumulative exports rising sharply from ₹4 lakh crore as of March 31, 2024, reflecting India's deeper integration into global value chains. 

Among the sectors, electronics has emerged as one of the biggest beneficiaries. Under the large-scale electronics manufacturing PLI scheme, mobile phone production has increased 2.4 times since the programme's launch, while imports have declined by around 77%. The government said 99.2% of mobile phones used in India are now manufactured domestically. 

The pharmaceutical sector has recorded cumulative sales of more than ₹3.64 lakh crore under the scheme. The PLI programme has enabled the domestic production of 1,931 pharmaceutical products, including 191 bulk drugs that are being manufactured in India for the first time, strengthening local manufacturing capabilities. 

In the bulk drugs segment, the government said manufacturing capacity of around 55,000 metric tonnes has been established across 26 critical active pharmaceutical ingredients (APIs), reducing import dependence for products such as Paracetamol, Levofloxacin, and Norfloxacin. 

The PLI scheme for medical devices has facilitated domestic production of advanced equipment, including CT scanners, MRI systems, cath labs, and ultrasonography machines. So far, 22 companies have commenced operations, commissioning 55 unique medical devices. 

In the telecom and networking products sector, the scheme has supported the development of indigenous 4G technology and strengthened domestic manufacturing capabilities for 5G telecom equipment, the government said. 

The PLI scheme for white goods has also significantly expanded local manufacturing of air-conditioner components. Compressor manufacturing capacity has increased from 1 million units in 2021 to 10 million units in 2025-26 while localisation of key components such as PCBAs and cross-flow fans has improved substantially, reducing import dependence. 

Prasada said the implementation of the PLI schemes is reviewed periodically by the Empowered Group of Secretaries (EGoS), chaired by the Cabinet Secretary, and the respective administrative ministries. Based on stakeholder feedback and implementation experience, modifications have been introduced in certain schemes to address operational challenges and improve execution. 

To enhance the effectiveness of the PLI programme, the government has undertaken measures such as periodic reviews, rationalisation of scheme guidelines, relaxation of select eligibility criteria, stronger project monitoring, regular stakeholder consultations, and faster resolution of implementation issues through the EGoS.